Study S000075

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01484262
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 1344
Start: 2011-11-14
Primary completion: 2014-10-31
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide; DRUG:insulin
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1123-5044

Registered primary outcomes

Diabetes-related quality of life assessed by ADDQoL (Audit of Diabetes-Dependent Quality of Life) [At the end of the observational period (52 weeks)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0024914	Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study. Lundershausen R, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association	2020	Nonrandomized study	PMID 30157532 DOI	registry reference RESULT:30157532